Form 4: FATE Therapeutics CEO Sells Shares for Tax Obligations

FATE Therapeutics President and CEO, Bahram Valamehr, sold 5,190 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Bahram Valamehr, President and CEO, and a Director of FATE Therapeutics Inc. (FATE), reported a transaction.
• On January 9, 2026, Valamehr disposed of 5,190 shares of FATE common stock.
• The shares were sold at a weighted average price of $1.0708 per share, with prices ranging from $1.055 to $1.085.
• This sale was a 'sell-to-cover' transaction, automatically executed to satisfy tax withholding obligations upon the vesting of 8,326 shares of Restricted Stock Units (RSUs).
• The RSUs were originally granted to Valamehr on January 25, 2022.
• Following this transaction, Valamehr beneficially owns 329,708 shares of FATE common stock directly.
• The transaction was not made at the discretion of the Reporting Person, but pursuant to an irrevocable election for tax withholding.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary 'sell-to-cover' transaction for tax purposes, which is a common occurrence for executives receiving equity compensation and does not indicate a change in the insider's view of the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell-to-cover' transactions and was not made at the discretion of the Reporting Person.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation and tax obligations, which is a common occurrence across publicly traded companies and does not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and represents a small fraction of the executive's total holdings.

Key Dates

Recommendation

The transaction reported is a routine 'sell-to-cover' for tax withholding purposes, not a discretionary sale. Such transactions are common for executives receiving equity compensation and typically do not reflect a change in the company's fundamentals or the insider's long-term outlook. Therefore, it does not provide a basis for a change in investment recommendation, and a 'hold' stance is maintained based solely on this filing.

Keywords

FATE Therapeutics, FATE, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Bahram Valamehr